Navigation Links
Dyadic International Upgraded By OTC Markets To "Current Information" Tier
Date:1/23/2013

JUPITER, Fla., Jan. 23, 2013 /PRNewswire/ -- Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzyme industries, announced today that it has been upgraded by OTC Markets to "Current Information" which is the highest trading tier on the OTC Pink marketplace. The disclosures required for this upgrade have been posted on the OTC Markets website (www.otcmarkets.com) under Dyadic's ticker symbol, "DYAI."

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic's President and CEO, Mark Emalfarb , stated, "Completion of the upgrade to OTC Pink Current Information is one of several positive steps Dyadic has taken to strengthen our stockholder base and build stockholder value by providing greater transparency through periodic press releases and quarterly and annual disclosures, financial statements and investor conference calls. The confidence and protections provided by these additional disclosures contribute to the significantly greater liquidity of the OTC Pink Current Information Tier as compared to the prior tier assigned to Dyadic."

The Current Information Tier applies to reporting companies that submit filings to regulators with powers of review and that make the filings publicly available and non-reporting companies that make current information publicly available on the OTC Disclosure and News Service pursuant to OTC Markets Guidelines for Providing Adequate Current Information. Disclosures are published pursuant to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of Rule 240.15c2-11 and the OTC Disclosure Guidelines.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzyme industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.  Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
2. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
3. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
4. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
5. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
6. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
7. Dyadic International Reports 2012 Third Quarter Financial Results
8. 12th U.S. Patent Issued To Dyadic International
9. UV Flu Technologies Expands Its International Footprint
10. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
11. International Attendance for Networking and Education at Informex Beyond Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... ... March 20, 2017 , ... ... interfere with the ability of endogenous hormones to regulate homeostasis via their ... activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and immunological disorders. EDC ...
(Date:3/20/2017)... CA (PRWEB) , ... March 20, 2017 , ... ... require expensive and laborious sample preparation methods in order to reduce the impact ... underappreciated outside of the area of elemental analysis. , This presentation will ...
(Date:3/20/2017)... Clara, CA (PRWEB) , ... March 20, 2017 , ... ... free AFM Demo on Friday, March 24, 2017 from 5-7pm at their ... demo, and a special presentation from imec Senior Researcher, Dr. Tae-Gon Kim. , Dr. ...
(Date:3/20/2017)...  Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating ... or the "Company") (NYSE: BIOA ). Such investors ... by visiting the firm,s site: www.bgandg.com/bioa . ... officers and/or directors have violated Sections 10(b) and 20(a) of ... ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has ... World Lung Imaging Workshop at the University of Pennsylvania. ... invited to deliver the latest data to world leaders ... event brings together leaders at the forefront of the ... lung imaging. "The quality of the ...
(Date:3/6/2017)... Calif. , March 6, 2017 ... and sales technology, today announced Predictive Sales Coach ... for infusing actionable sales intelligence into Salesforce. This ... automatically enable their sales organizations with deep knowledge ... that allow for intelligent engagement. Predictive Sales Coach ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
Breaking Biology News(10 mins):